HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Tu 2208

potent inhibitor of squalene epoxidase; structure in first source

Also Known As:

Tu2208

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - Tu 2208: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - Tu 2208: 1

Experts

1.	Bouchard, G: 1 article (01/2004)
2.	Carey, M C: 1 article (01/2004)
3.	Clarke, G A: 1 article (01/2004)
4.	Paigen, B: 1 article (01/2004)

Related Diseases

1.	Gallstones (Gallstone) 01/01/2004 - "We determined gall stone phenotype, HMGR activity, biliary lipid secretion rates, and counterregulatory events in male C57L/J mice and gall stone resistant AKR treated with Tu 2208 (30-60 mg/kg/day) or Ro 48-8071 (30-100 mg/kg/day), while ingesting chow or the lithogenic diet. " 01/01/2004 - "As this occurs in the gall stone susceptible C57L/J inbred mouse, we employed two cholesterol biosynthesis inhibitors, Tu 2208 and Ro 48-8071, potent inhibitors of squalene epoxidase and oxidosqualene-lanosterol cyclase, respectively, to assess their potential in preventing cholesterol cholelithiasis in the C57L/J mouse strain. "
2.	Cholelithiasis 01/01/2004 - "As this occurs in the gall stone susceptible C57L/J inbred mouse, we employed two cholesterol biosynthesis inhibitors, Tu 2208 and Ro 48-8071, potent inhibitors of squalene epoxidase and oxidosqualene-lanosterol cyclase, respectively, to assess their potential in preventing cholesterol cholelithiasis in the C57L/J mouse strain. "

Related Drugs and Biologics

1.	Squalene Monooxygenase (Squalene Epoxidase)
2.	Lipids
3.	Lanosterol
4.	Cholesterol
5.	oxidosqualene
6.	Ro 48-8071